Peripheral Neuropathic Pain Management

Ferdia’s goal is to develop a long-acting peptide therapeutic for peripheral neuropathic pain, designed to provide up to one week of analgesia through infusion or to be administered as a once-weekly subcutaneous injection for ongoing pain management. 

Fer-176, our lead asset, has shown sustained efficacy in preclinical models of inflammatory and postoperative pain, with pharmacokinetics supporting once-weekly dosing in humans. In the CFA rat model (figure), Fer-176 provided over 24 hours of analgesia, demonstrated by improved thresholds in the Von Frey hypersensitivity test. In contrast, indomethacin and J-2156, a short-acting SSTR4 agonist, provided only short-term relief.